Develop a Value Proposition for your Biosimilars that Appeals to Payers, Providers, and Patients
World Congress’ Biosimilars Market Access & Commercialization Executive Boardroom examines the first wave of biosimilars approved and marketed in the U.S. With drug pricing for biologics highly scrutinized, biosimilars aim to serve as an equivalent alternative, but face numerous challenges. Payer relationships and familiarity with originator products, provider and patient uncertainty serve as roadblocks that require the manufacturers to provide a more robust value proposition and education around biosimilars. Over the three days, topics such as stakeholder education, comparative pricing and reimbursement techniques, and establishing best practices from successful launches will be discussed in order to help your biosimilars market access operations.
For the first time ever, join a summit that will bring together four extremely important therapy topics for 2018: Biosimilars, Rare Disease, Oncology, and Cell & Gene Therapy. A day of shared plenary sessions will provide high-level guidance from key stakeholders, such as policy, payers, senior manufacturing executives and more, in order for an enhanced value proposition when launching new products.
Professor Emeritus of Economics Widener University and Adjunct Faculty
College of Population Health Thomas Jefferson University
Former Vice President, National Medical Director, Pharmaceutical Policy and Strategy